You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020174025
Dec 20202208
Jan 202158016
Feb 202110409
Mar 2021232021
Apr 2021290029
May 202189027
Jun 20210019
Jul 20210019
Aug 20210013
Sep 2021007
Oct 2021115027
Nov 2021106031
Dec 20218405
Jan 2022110016
Feb 2022142010
Mar 2022142013
Apr 2022174011
May 2022110011
Jun 202212209
Jul 202213607
Aug 2022144010
Sep 2022106017
Oct 2022140020
Nov 2022166015
Dec 20227009
Jan 2023122016
Feb 2023106011
Mar 202394015
Apr 2023108018
May 202310209
Jun 20237408
Jul 202398014
Aug 2023125010
Sep 20239807
Oct 202313008
Nov 2023156023
Dec 202310608
Jan 202460010
Feb 2024118022
Mar 2024148038
Apr 202466019
May 202496022
Jun 20244408
Jul 202466013
Aug 20245807
Sep 202492011
Oct 20246008
Nov 20245009
Dec 202484011
Jan 202554021
Feb 202516014
Mar 2025009
Apr 20250012
May 20250010
Jun 2025009
Total51670804